-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Applied UV Declares Monthly Preferred Stock Dividend
Applied UV Declares Monthly Preferred Stock Dividend
MOUNT VERNON, NY / ACCESSWIRE / February 22, 2022 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied UV's 10.5% Series A Cumulative Perpetual Preferred Stock.
Holders of the 10.5% Series A Cumulative Perpetual Preferred Stock (NASDAQ:AUVIP) shall receive a cash dividend equal to $0.21875 per share.
The preferred dividend will be paid on or about March 15, 2022, to respective holders of record at the close of business on March 4, 2022.
About Applied UV
Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® products for air purification, developed for NASA and FDA Cleared as class II medical devices, utilize a proprietary photo-catalytic bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous pathogens, destructive VOCs and biological gasses into harmless water vapor without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, and homes.
For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: and,
Forward-Looking Statements
The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.
For additional Company Information:
Applied UV Inc.
Max Munn
Applied UV Interim CEO
Max.munn@sterilumen.com
CONTACT
Brett Maas, Managing Principal
Hayden IR
brett@haydenir.com
(646) 536-7331
SOURCE: Applied UV, Inc.
View source version on accesswire.com:
MOUNT VERNON, NY / ACCESSWIRE / February 22, 2022 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied UV's 10.5% Series A Cumulative Perpetual Preferred Stock.
纽约州芒特弗农/ACCESSWIRE/2022年2月22日/亚洲网加利福尼亚州圣克拉拉5月13日电应用紫外线公司(纳斯达克代码:AUVI)(以下简称“公司”)是一家应用紫外线消除病原体的技术公司,该公司将窄范围紫外光的能量用于表面积,并将催化生物转化技术应用于空气净化,以安全、彻底和自动地消灭病原体。该公司董事会今天宣布,其董事会已批准向应用紫外光持有的10.5%A系列累积永久优先股的持有者发放现金股息。
Holders of the 10.5% Series A Cumulative Perpetual Preferred Stock (NASDAQ:AUVIP) shall receive a cash dividend equal to $0.21875 per share.
持有10.5%A系列累积永久优先股(纳斯达克代码:AUVIP)的股东将获得相当于每股0.21875美元的现金股息。
The preferred dividend will be paid on or about March 15, 2022, to respective holders of record at the close of business on March 4, 2022.
优先股息将在2022年3月15日左右支付给2022年3月4日收盘时各自登记在册的持有者。
About Applied UV
Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® products for air purification, developed for NASA and FDA Cleared as class II medical devices, utilize a proprietary photo-catalytic bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous pathogens, destructive VOCs and biological gasses into harmless water vapor without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, and homes.
关于应用的UV
应用紫外线公司专注于医疗保健、酒店、商业和市政市场的感染控制技术的开发和收购。该公司有两家全资子公司--SteriLumen,Inc.(“SteriLumen”)和Munn Works,LLC(“Munn Works”)。SteriLumen的互联数据驱动消毒平台™应用紫外线的力量,安全、彻底和自动地摧毁病原体,应对医疗保健获得性感染(HAI)的挑战。该公司的Lumicide™平台针对医院、酒店、商业设施和其他公共场所等客户周转率高的设施,采用多种专利设计的紫外线LED,用于高流量区域及其周围的感染控制,包括水槽和洗手间,杀灭驻留在设备附近硬面上的细菌、病毒和其他病原体。该公司获得专利的下水道内消毒装置--鲁米德排水沟是市场上唯一一种能够解决这一病原体密集的关键部位的产品。SteriLumen的空气净化产品是为美国国家航空航天局(NASA)和美国食品和药物管理局(FDA)开发的II级医疗设备,利用专有的光催化生物转化技术将空气吸入反应室,将破坏性霉菌、微生物、危险病原体、破坏性VOC和生物气体转化为无害的水蒸气,而不会产生臭氧或其他有害副产品。AIROSIDE®应用包括医疗保健、酒店、食品杂货连锁店、酿酒设施、商业地产、学校、牙科诊所和家庭。
For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: and,
有关应用UV公司及其子公司的更多信息,请访问以下网站:
Forward-Looking Statements
The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.
前瞻性陈述
本文包含的信息可能包含“前瞻性陈述”。前瞻性陈述反映了当前对未来事件的看法。在本新闻稿中使用的“预期”、“相信”、“估计”、“预期”、“未来”、“打算”、“计划”或这些术语的否定或与我们或我们的管理层相关的类似表述都是前瞻性陈述。这些陈述包括但不限于,本新闻稿中包含的有关应用UV管理层对其业务战略、未来经营业绩以及流动性和资本资源前景的看法的陈述。前瞻性陈述基于公司目前对其业务、经济和其他未来状况的预期和假设。由于前瞻性陈述涉及未来,它们受到难以预测的固有不确定性、风险和环境变化的影响。该公司的实际结果可能与前瞻性陈述中预期的大不相同。它们既不是对历史事实的陈述,也不是对未来业绩的保证。因此,我们告诫您不要依赖这些前瞻性陈述中的任何一种。可能导致本公司实际结果不同的因素或事件可能会不时出现,本公司不可能预测所有这些因素或事件。公司不能保证未来的结果、活动水平、业绩或成就。除非适用法律(包括美国证券法)要求,否则公司不打算更新任何前瞻性陈述,以使这些陈述与实际结果相符。
For additional Company Information:
Applied UV Inc.
Max Munn
Applied UV Interim CEO
Max.munn@sterilumen.com
有关更多公司信息,请访问:
应用UV公司
麦克斯·穆恩
应用UV临时首席执行官
邮箱:Max.munn@sterilumen.com
CONTACT
Brett Maas, Managing Principal
Hayden IR
brett@haydenir.com
(646) 536-7331
接触
布雷特·马斯(Brett Maas),管理校长
海登红外光谱
邮箱:Brett@haydenir.com
(646) 536-7331
SOURCE: Applied UV, Inc.
资料来源:应用UV,Inc.
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧